Book a Meeting

Non-Fucosylated Anti-Human RELP (CNTO 4164) Therapeutic Antibody (CAT#: BioBet-1576ZP) Datasheet

Target
RELP
Isotype
IgG
Description
ADCC-Enhanced anti-RELP (CNTO 4164) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced RELP antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
REG4
Full Name
Reg Like Protein
Background
regenerating islet-derived family, member 4
Alternative Names
REG4; regenerating islet-derived family, member 4; GISP; RELP; REG-IV; regenerating islet-derived protein 4; REG-4; reg IV; REG-like protein; regenerating gene type IV; gastrointestinal secretory protein; regenerating islet-derived protein IV;
Gene ID
83998
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with REG4 include Ulcerative Colitis and Pseudomyxoma Peritonei.
Related Pathways
Its related pathways are Gastric cancer and Adhesion.
Function
Lectin that does not depend on calcium, shows mannose binding specificity, and can maintain carbohydrate recognition activity in an acidic environment. May be involved in the inflammation and metaplasia of the gastrointestinal epithelium.
Post-translational modifications
1.Glycosylation at Asn50 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
CNTO 4164
Host
Human
Species Reactivity
Human
Description
The novel anti-RELP fusion antibody target provides a method for modulating or treating at least one RELP protein related disease, such as leukemia, lymphoma, carcinoma, solid tumors.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human RELP (CNTO 338) Therapeutic Antibody (CAT#: BioBet-1577ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.